Sinovac Biotech (SVA) Stock Price, News & Analysis

Company Overview

Sinovac Biotech Ltd. is a China-based biopharmaceutical company focused on the research, development, manufacture and commercialization of vaccines for human infectious diseases. The company develops products for both routine immunization programs and emerging public-health needs, with operations centered in China.

Sinovac’s product portfolio has included CoronaVac, an inactivated COVID-19 vaccine, as well as Healive, a hepatitis A vaccine, and Bilive, a combined hepatitis A and B vaccine. The company has also developed vaccines targeting seasonal influenza, pneumococcal disease and varicella. Product availability and regulatory authorization vary by market.

Founded in 2001, Sinovac expanded its international presence through the distribution and regulatory approval of its vaccines in a number of countries, particularly in Asia, Latin America and other emerging markets. Its COVID-19 vaccine was used in national immunization programs across multiple geographies. Weidong Yin has historically served as the company’s chairman and chief executive officer.

Key Stats

• Today's Range: $6.47 to $6.47
• 50-Day Range: $6.47 to $6.47
• 52-Week Range: $5.73 to $8.75
• Volume: N/A
• Average Volume: N/A
• Market Capitalization: $644.67 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $1.00
• Consensus Rating: Buy

Sinovac Biotech Stock Analysis - MarketRank™

Sinovac Biotech scored higher than 31% of companies evaluated by MarketBeat, and ranked 762nd out of 907 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 1.7 / 5
• Analyst Rating: Buy

Consensus Rating

Sinovac Biotech has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on no strong buy ratings, 1 buy rating, no hold ratings, and no sell ratings.

Downside Risk

Sinovac Biotech has a consensus price target of $1.00, representing about 84.5% downside from its current price of $6.47.

Amount of Analyst Coverage

Sinovac Biotech has only been the subject of 1 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: N/A

Price to Book Value per Share Ratio

Sinovac Biotech has a P/B Ratio of 0.07. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

Short Interest

• Score: 3.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

0.09% of the float of Sinovac Biotech has been sold short.

Short Interest Ratio / Days to Cover

Sinovac Biotech has a short interest ratio ("days to cover") of 0, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Sinovac Biotech does not currently pay a dividend.

Dividend Growth

Sinovac Biotech does not have a long track record of dividend growth.

News and Social Media

• Score: 4.3 / 5
• News Sentiment: N/A

News Sentiment

Sinovac Biotech has a news sentiment score of 1.82. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.72 average news sentiment score of Healthcare companies.

News Coverage This Week

MarketBeat has tracked 1 news article for Sinovac Biotech this week, compared to 0 articles on an average week.

MarketBeat Follows

1 people have added Sinovac Biotech to their MarketBeat watchlist in the last 30 days.

Company Ownership

• Score: 0.5 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Sinovac Biotech insiders have not sold or bought any company stock.

Percentage Held by Insiders

12.79% of the stock of Sinovac Biotech is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

Sinovac Biotech has minimal institutional ownership at this time.

Company Calendar

• Today: 9/26/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Healthcare
• Industry: Biotechnology
• Sub-Industry: Biotechnology
• Current Symbol: NASDAQ:SVA
• CIK: 1084201
• Web: www.sinovac.com
• Phone: 86-10-5693-1800
• Fax: 86-10-5693-1800
• Employees: 3,008
• Year Founded: 2001

Price Target and Rating

• Average Price Target for Sinovac Biotech: $1.00
• High Price Target: $1.00
• Low Price Target: $1.00
• Potential Upside/Downside: -84.5%
• Consensus Rating: Buy
• Rating Score (0-4): 3.00
• Research Coverage: 1 Analysts

Profitability

• EPS (Trailing Twelve Months): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: 0.04
• Current Ratio: 6.07
• Quick Ratio: 5.97

Sales & Book Value

• Annual Sales: $386.01 million
• Price / Sales: 1.67
• Cash Flow: $0.54 per share
• Price / Cash Flow: 11.89
• Book Value: $89.01 per share
• Price / Book: 0.07

Miscellaneous

• Outstanding Shares: 99,640,000
• Free Float: 86,894,000
• Market Cap: $644.67 million
• Optionable: Optionable
• Beta: 0.80